Clinical Trials Browser

Uveal Melanoma × Nivolumab × 90 days × Clear all

NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT03686124 2026-02-18

ACTengine

Phase 1/2 Recruiting

DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT06581406 2026-02-18

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT04552223 2026-02-11

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Phase 2 Completed

27 enrolled 9 charts

Uveal Melanoma

NCT03025256 2026-01-08

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Phase 1 Active not recruiting

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus